Welcome to our dedicated page for Aeon Biopharma news (Ticker: AEON), a resource for investors and traders seeking the latest updates and insights on Aeon Biopharma stock.
AEON Biopharma develops ABP-450 (prabotulinumtoxinA) as a proposed biosimilar to BOTOX (onabotulinumtoxinA) for therapeutic indications. Company announcements focus on analytical similarity work, FDA biosimilar pathway interactions, scientific presentations, and the regulatory strategy supporting ABP-450 development.
Recurring AEON updates also address operating and financial results, liquidity and going-concern disclosures, shareholder meeting matters, inducement equity awards, executive and governance changes, capital-structure actions, and NYSE American continued-listing compliance.
AEON Biopharma (NYSE: AEON) reported inducement grants totaling 392,158 restricted stock units (RSUs) to newly hired non-executive employees, approved under the company’s 2025 Inducement Incentive Plan.
The grants have a grant date of December 11, 2025, vesting commencement dates in December 2025, and vest 25% annually over four years. Awards are subject to the Inducement Plan and individual RSU agreement terms and were issued as inducement material under Section 711 of the NYSE American Company Guide.
AEON Biopharma (NYSE: AEON) announced a definitive exchange with Daewoong on Dec 15, 2025 converting $15 million of convertible notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash‑exercise warrant for 8 million common shares. The warrants, if exercised, could provide over $8 million of additional cash proceeds. The transaction is subject to stockholder approval and is expected to eliminate more than 90% of AEON’s outstanding debt, altering the company’s capital structure and Daewoong’s strategic alignment with AEON.
AEON (NYSE American: AEON) announced a first closing of its previously announced PIPE on Nov 18, 2025 that generated approximately $1.79 million in proceeds. The company said the proceeds, together with anticipated second-closing funds, will support its analytical program and are expected to accelerate ABP-450 biosimilar development by up to six months.
AEON also disclosed the FDA proposed a new date of Jan 21, 2026 for its BPD Type 2a meeting (previously Nov 19, 2025); the meeting will review analytical plans and initial biosimilarity data, and the FDA did not cite scientific or program-related issues in the scheduling change.
AEON (NYSE:AEON) reported Q3 2025 results and a business update on Nov 14, 2025 highlighting positive analytical biosimilarity data for ABP-450 and strategic financings. LC-MS showed a 100% amino-acid sequence match to BOTOX across visible portions and 93–99% sequence coverage across five proteins; the analytical package was submitted ahead of an FDA Type 2a meeting on Nov 19, 2025.
The company announced a $6 million PIPE and a proposed Daewoong note exchange expected to cut outstanding debt by >90%, accelerate the ABP-450 program by up to six months, and extend cash runway into Q2 2026. Cash was $5.9 million at Sept 30, 2025 (pre-Pipe).
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company developing botulinum toxin treatments, has granted 102,880 restricted stock units (RSUs) to newly hired non-executive employees. The RSUs were approved under the AEON 2025 Inducement Incentive Plan, with a grant and vesting commencement date of May 21, 2025. The RSUs will vest over a four-year period, with 25% vesting annually. These awards serve as employment inducements and comply with Section 711 of NYSE American LLC Company Guide.
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company developing botulinum toxin complex treatments, has announced its participation in the upcoming Aegis Capital Corp. 2025 Virtual Conference. The company's President and CEO, Rob Bancroft, will deliver a corporate overview presentation on Wednesday, May 21st at 7:00 a.m. PT / 10:00 am ET. AEON's focus is on developing treatments for multiple therapeutic indications using their botulinum toxin complex technology.
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company developing botulinum toxin treatments, has received acceptance from NYSE American for its compliance plan. The exchange has granted AEON until August 3, 2026 to meet minimum market capitalization and stockholders' equity requirements under Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide.
During this period, AEON will undergo periodic reviews to assess progress toward compliance goals. If the company fails to regain compliance by the deadline or doesn't show sufficient progress, NYSE American may initiate delisting proceedings.
AEON Biopharma (NYSE: AEON) has announced the approval of inducement awards in connection with Rob Bancroft's appointment as President and Chief Executive Officer. The Company's Compensation Committee has approved two key grants:
1. A non-qualified stock option to purchase 59,034 shares of AEON Class A common stock, with an exercise price matching the closing price on the grant date
2. 177,103 restricted stock units (RSUs) to be granted upon Form S-8 registration filing or employment start date
Both awards will vest over a four-year period, with 25% vesting annually from the employment start date. These grants are being made under AEON's 2025 Employment Inducement Incentive Award Plan and comply with Section 711 of NYSE American Company Guide.
AEON Biopharma (NYSE: AEON) has appointed Rob Bancroft as President and Chief Executive Officer, effective April 29, 2025. Bancroft, who brings over 25 years of leadership experience in life sciences, will also join AEON's Board of Directors. He previously served as General Manager of Therapeutics at Revance Therapeutics and led Smith & Nephew's Biotherapeutics division.
The appointment comes as AEON advances its ABP-450 program through the 351(k) biosimilar regulatory pathway. ABP-450 shares the same 900kDa molecular weight as BOTOX and aims to provide a comparable alternative in the $3B botulinum toxin therapeutics market. The company expects to announce results from its Biosimilar BPD Type 2a FDA meeting in the second half of 2025.